Biopharma: Hantavirus Q&A

Research evidence excerpt

Biopharma: Hantavirus Q&A

Update

May 12, 2026 02:14 PM GMT

Morgan Stanley & Co. LLCMBiopharma | North America Terence C Flynn, Ph.D.

Equity Analyst

Hantavirus Q&A Terence.Flynn@morganstanley.comChris Yu, J.D., Ph.D. +1 212 761-2230

Chris.L.Yu@morganstanley.com +1 212 761-2535

With increasing attention surrounding the recent Andes Connor M Massari

hantavirus outbreak linked to cruise travel, within we review EquityConnor.Massari@morganstanley.comAnalyst +1 212 761-2417

hantavirus transmission, clinical risk, prevention, and the vaccine Alexander Yevdokimov, Ph.D.

Research Associate

landscape. CDC currently assesses the overall risk to the U.S. Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

public and travelers as extremely low. Hailey Horowitz

Hailey.Horowitz@morganstanley.com +1 212 761-5264

At a high level, we think the risk of a global pandemic caused by hantaviruses is

Damien H Kerner

very low and CDC currently assesses the overall risk to the U.S. public and Research Associate

travelers as extremely low. Damien.H.Kerner@morganstanley.com +1 212 761-3829

Biotechnology

Hantavirus, a rodent-borne family of viruses that can cause severe pulmonary North America

disease, and is typically transmitted through exposure to infected rodents: A Industry View Attractive

recent multi-country cluster of Andes hantavirus cases linked to the MV Hondius

cruise ship, including nine reported cases and three deaths as of May 11, 2026, has

raised concerns around outbreak risk and raised some investor questions regarding

hantavirus vaccine development. We note that hantavirus outbreaks have occurred

previously and generally remain localized, as most infections result from inhaling

particles from infected rodent urine, droppings, or saliva rather than sustained